Chronic lymphocytic leukemia (CLL) affects approximately 4.6 per 100,000 individuals ... In stage III, lymphocytosis is evident, and the patient is anemic; enlarged lymph nodes/liver/spleen are not ...

Panelists discuss how JAK inhibitor therapy can benefit patients with intermediate-1–risk myelofibrosis despite being studied primarily in higher-risk patients in the COMFORT and JUMP trials.